Indian Pharma

1,966 views

Published on

Published in: Business, News & Politics
1 Comment
7 Likes
Statistics
Notes
No Downloads
Views
Total views
1,966
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
1
Likes
7
Embeds 0
No embeds

No notes for slide

Indian Pharma

  1. 1. INDIAN PHARMA
  2. 2. INTRODUCTION  India is today recognized as one of the leading global players in pharmaceuticals.  Indiian pharma industry has shown tremendous progress in terms of infrastructure development, technology base & wide range of products.
  3. 3. Contd…. The industry now produces bulk drugs  belonging to all major therapeutic groups requiring complicated manufacturing processes and has also developed excellent GMP (Good Manufacturing Practices) compliant facilities for the production of different dosage forms. The strength of the industry is in  developing cost effective technologies in the shortest possible time for drug intermediates and bulk activities without compromising on quality.
  4. 4. THE DOMESTIC PHARMA INDUSTRY pharma industry has  Domestic recently achieved some historic milestones through a leadership position and global presence as a world class cost effective generic drugs' manufacturer of AIDS medicines.  Many Indian companies maintain highest standards in Purity, Stability and International Safety, Health and Environmental (SHE) protection in production and supply of bulk drugs even to some innovator companies.
  5. 5. Contd…  Many Indian companies are part of an agreement where major AIDS drugs based on Lamivudine, Stavudine, Zidovudine, Nevirapine will be supplied to Mozambique, Rwanda, South Africa and Tanzania which have about 33% of all people living with AIDS in Africa. Yet another US Scheme envisages sourcing Anti Retrovirals from some Indian companies whose products are already US FDA approved.
  6. 6. Contd… Increasing number of Indian  pharmaceutical companies have been getting international regulatory approvals for their plants from agencies like USFDA (USA), MHRA (UK), TGA (Australia), MCC (South Africa), Health Canada etc.  Indian companies are now seeking more Abbreviated New Drug Approvals (ANDAs) in USA in specialized segments like anti-infective, cardio vascular and central nervous system groups.
  7. 7. FACTS & FIGURES The annual turnover of Indian  pharmaceuticals industry in 2006-07 was approx $17 billion (over 68,000 crore).  The share of export of drugs, pharmaceuticals, & fine chemicals was more than 24,000 cr.(around us $ 6 billion) .
  8. 8. Contd… Europe accounts for the highest share of  over 23% of Indian Pharma exports followed by North America and Asia. Exports to USA have crossed the land mark figure of US $1 billion during 2006- 07.  It is estimated that by the year 2010, the Indian pharmaceutical industry has the potential to achieve over Rs.1,00,000 crore production of formulations and bulk drugs.
  9. 9. PRODUCTION During 2007-08 several proposals for  technology transfer including joint ventures, proposals for foreign direct investment, setting up of new undertakings/expansion of existing units (manufacture of new articles in the existing units) have been received and processed. Following the de-licensing of the pharmaceutical industry, industry is now required to submit Industrial Entrepreneurial Memorandums (lEMs) for the manufacture of various bulk drugs/drug intermediates /formulations.
  10. 10. EXPORTS Year Exports(Rs. In Growth(%) crore) 2003-04 15213 18.61 2004-05 17857 17.38 2005-06 22216 24.41 2006-07 24942 12.27 Source: Directorate General of Commercial Intelligence and Statistics  (DGCIS) Kolkata
  11. 11. INDUSTRY STRENGTHS  Knowledge based Industry  Large manufacturing base for high quality drugs and formulations  Developing cost effective technologies for drug intermediaries and bulk actives without a compromise on quality
  12. 12. Contd….. Cost advantage in terms of drug  production, maintenance of high standards in terms of purity, stability and international safety, health and environment protection  Tremendous export potential  Major driver of growth in the future  Strong scientific and technical manpower
  13. 13. Contd…. World class national laboratories in  process development  Increasing balance of trade in the sector  An excellent centre for clinical trials  Competencies in chemistry and process development
  14. 14. THANK YOU

×